Loading...
VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice
BACKGROUND: Chronic mucocutaneous candidiasis (CMC) treatment often induces drug resistance, posing long-term challenges. A novel broad-spectrum fungal CYP51 inhibitor, VT-1598, specifically targets fungal CYP51, but not human CYP enzymes. OBJECTIVES: To determine the efficacy of VT-1598 in the trea...
Na minha lista:
Udgivet i: | J Antimicrob Chemother |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Oxford University Press
2018
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6054247/ https://ncbi.nlm.nih.gov/pubmed/29788070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky170 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|